Search

Displaying results 1841 - 1850 of 10000 in total
  1. Drug

    Terlipressin

    go.drugbank.com/drugs/DB02638
    ApprovedInvestigational

    Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor.[A2601] It is a prodrug of [lypressin], or lysine vasopressin. … [L43217] As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone.

  2. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has made it a desirable target in the treatment these B-cell malignancies.

  3. Drug

    Corticorelin ovine triflutate

    go.drugbank.com/drugs/DB09067
    Approved

    It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. … It provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ectopic ACTH syndrome (an ectopic source of ACTH excess).

  4. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. … s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659].

  5. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … Thonzonium is a monocationic surface-active agent with surfactant and detergent properties.

  6. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the

  7. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections [L2570], [L2571]. … The acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting.

    Synonyms: 6-n-amyl-m-cresol, 6-n-pentyl-m-cresol
  8. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing

  9. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    [A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. … [A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation.

  10. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in